Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02906059 · ClinicalTrials.gov registry record · Phase 1
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02906059 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 7 participants.
The verdict
NCT02906059, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether combination therapy of irinotecan with AZD1775 is safe and effective in treating mutated metastatic colorectal cancer patients.
Interventions
- DRUG Irinotecan
- DRUG AZD1775
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-09 |
| Est. Completion | 2020-03-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02906059
The ClinicalTrials.gov registry entry for NCT02906059 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irinotecan is the first listed.
NCT02906059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02906059 about?
NCT02906059 is a clinical study titled "Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer". The purpose of this study is to determine whether combination therapy of irinotecan with AZD1775 is safe and effective in treating mutated metastatic colorectal cancer patients.
What is the current status of trial NCT02906059?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2016-09. Estimated completion is 2020-03-12.
What interventions are being tested in trial NCT02906059?
The interventions under investigation include: Irinotecan (DRUG), AZD1775 (DRUG).
Who is sponsoring clinical trial NCT02906059?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.